Similar articles

• Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines.

  Forsgren A, Riesbeck K, Janson H. Forsgren A, et al. Clin Infect Dis. 2008 Mar 1;46(5):726-31. doi: 10.1086/527396. Clin Infect Dis. 2008. PMID: 18230042 Review.
• Nontypeable Haemophilus influenzae as a pathogen in children.

  Murphy TF, Faden H, Bakaletz LO, Kyd JM, Forsgren A, Campos J, Virji M, Pelton SI. Murphy TF, et al. Pediatr Infect Dis J. 2009 Jan;28(1):43-8. doi: 10.1097/INF.0b013e318184dba2. Pediatr Infect Dis J. 2009. PMID: 19057458 Review.
• Vaccines for Moraxella catarrhalis and non-typeable Haemophilus influenzae.

  McMichael JC, Green BA. McMichael JC, et al. Curr Opin Investig Drugs. 2003 Aug;4(8):953-8. Curr Opin Investig Drugs. 2003. PMID: 14508879 Review.
• Investigation of the potential of a 48 kDa protein as a vaccine candidate for infection against nontypable Haemophilus influenzae.

  Webb DC, Otczyk DC, Cripps AW. Webb DC, et al. Vaccine. 2007 May 16;25(20):4012-9. doi: 10.1016/j.vaccine.2007.02.048. Epub 2007 Mar 8. Vaccine. 2007. PMID: 17379362
• New vaccines against otitis media: projected benefits and cost-effectiveness.

  O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen VL, Mehta J, Colborn DK, Lieu TA. O'Brien MA, et al. Pediatrics. 2009 Jun;123(6):1452-63. doi: 10.1542/peds.2008-1482. Pediatrics. 2009. PMID: 19482754